This course will provide an intensive, topics-based review of basic science topics pertinent to the clinical practice of veterinary oncology. The course will feature in-depth reviews of several topics of general interest to clinical oncology, as well as a keynote lecture series describing the scientific rationale for several specific emerging therapeutic options for treating small animal cancers. The course is tailored to be of interest to practicing Diplomates as well as candidates preparing for the oncology certifying exam.
Upon completion of the course, you will be able to:
Your registration fee includes:
- Demonstrate proficiency in recommending the use of molecular testing and functional imaging studies for diagnosis and prognostication in small animal cancer patients.
- Describe common clinical trial designs involving cancer patients, as well as the objectives, limitations, and interpretation of results of each trial design.
- Describe the interaction of cancer development with the immune system, and how the immune system can be harnessed in cancer therapy.
- Describe the indications, technical specifications, and adverse events associated with hematopoietic stem cell transplantation in small animals with hematologic malignancies.
- Identify cancer-bearing animals that may be candidates for new and emerging therapies, and be able to critically evaluate the utility of these therapies for specific small animal patients.
- Lecture Proceedings
- Daily refreshment breaks and snacks
- Lunch on Monday and Tuesday
- Transportation between the Courtyard Marriott Last Vegas Henderson/Green Valley and the Oquendo Center
RACE Application Status:
This program has been approved for 16 hours of continuing education credit in jurisdictions which recognize RACE approval.
Michael Childress, DVM, MS, PhD, DACVIM (Oncology) (Course Leader)
Associate Professor of Comparative Oncology, Purdue University
Dr. Michael Childress received his DVM degree in 2004 from the Virginia-Maryland Regional College of Veterinary Medicine. Subsequently, he completed a rotating internship at Kansas State University and an oncology internship at the University of Georgia, before completing a 3-year residency/master’s degree program in comparative oncology at Purdue from 2006-2009. He joined the faculty of the Purdue College of Veterinary Medicine in 2009, where he is currently an associate professor of comparative oncology and head of the medical oncology section. His research focuses on the study of naturally-occurring canine lymphomas as a translational model for non-Hodgkin lymphomas in humans.
Matthew Atherton, BVCs, MVM, PhD, DipECVIM-CA (onc), MRCVS
University of Pennsylvania
Dr. Matt Atherton completed veterinary school at the University of Bristol. Following three years in mixed practice Matt undertook a rotating internship at the Royal Veterinary College. Matt gained board certification in medical oncology following residency training at the University of Glasgow and was awarded Master of Veterinary Medicine for researching the canine serum proteome. Subsequently he defended his PhD at McMaster University with data from this research enabling “first-in-man” oncolytic virotherapy trials. Matt is currently the Shuman Translational Research Fellow at Penn Vet where his clinical work and research focuses on cellular immunotherapy for canine cancer patients.
Anne Avery, DVM, PhD
Associate Professor, Colorado State University
Dr. Anne Avery completed her PhD in Immunology at Cornell University, and veterinary school at the University of Pennsylvania where she graduated in 1990. After an internship in small animal medicine at Penn, she did her post-doctoral training at the Dana-Farber Cancer Institute in Boston. She moved to CSU’s college of Veterinary Medicine in 1994 and is now Associate Professor in the Department of Microbiology, Immunology and Pathology, and Director of the Clinical Immunology Laboratory. The goals of the laboratory are to provide clinically relevant diagnostic information about lymphoproliferative disorders, and to conduct research on the biology of these diseases.
Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM
Assistant Clinical Professor of Oncology, University of Minnesota
Dr. Antonella Borgatti completed her DVM from the University of Torino, Italy. She pursued specialized training in oncology at North Carolina State University where she subsequently remained as a Research Associate, Oncology Intern, and Clinical Instructor in Oncology. She completed a Residency in Comparative Oncology at Purdue University where she also received a Master of Sciences Degree in 2006.
Dr. Borgatti joined the faculty at the University of Minnesota in 2008. The main focus of her research has been to develop alternative, targeted, biological drugs against chemotherapy refractory solid tumors in companion animals and evaluate their translational potential and applicability for treatment of human disease.
Erin Dickerson, PhD
Associate Professor, University of Minnesota
Dr. Erin Dickerson received her PhD in biochemistry from the University of Wisconsin-Madison in 1997. She then spent several years at the School of Veterinary Medicine in Madison and the Georgia Institute of Technology developing targeted drug approaches to treat cancer. Dr. Dickerson returned to the upper Midwest in 2009 and joined the faculty at the University of Minnesota and the Masonic Cancer Center. She has developed a research program devoted to studying canine hemangiosarcoma, and her group is working on new approaches to treat this disease.
Amanda Guth, DVM, PhD
Assistant Professor, Colorado State University
Dr. Amanda Guth is an assistant professor in the Department of Clinical Sciences at Colorado State University. After earning her DVM from Colorado State University, she started a post-doc position studying tumor immunology that led to her present day interest in understanding the immune response to tumors.
Dr. Guth's current interests lie in combining novel ways to block immune-inhibitory cells to enhance the effects of tumor vaccines and other immunotherapies. She has recently been focusing on developing vaccines targeting cancer stem cells and studying a novel method for generating whole cell, autologous tumor vaccines, both in mouse models and in client-owned dogs.
Matti Kiupel, DVM, Dr. Vet Me., Dr. Habil, MVSC, PhD, DACVP
Professor, Michigan State University
Dr. Matti Kiupel is an anatomic pathologist and professor in the Department of Pathobiology and Diagnostic Investigation and the Veterinary Diagnostic Laboratory at Michigan State University. He oversees the histology and immunohistochemistry laboratory, the largest veterinary diagnostic molecular pathology laboratory in the country. He has published more than 300 peer-reviewed papers and numerous book chapters in veterinary and comparative pathology, specifically tumorpathology, and is the editor of the “Surgical Pathology of Tumors in Domestic Animals” (former WHO fascicles) series.
Amy LeBlanc, DVM, DACVIM (Oncology)
Director, Comparative Oncology Program, National Cancer Institute
Dr. Amy LeBlanc is the Director of the intramural National Cancer Institute’s Comparative Oncology Program. She conducts preclinical mouse and translational canine studies designed to inform the drug and imaging agent development path for human cancer patients; these studies evaluate immunotherapeutics, targeted small molecules, oncolytic viruses, medical devices, and cancer imaging agents. She directly oversees the NCI Comparative Oncology Trials Consortium (COTC), which provides infrastructure necessary to connect participating veterinary academic institutions with stakeholders in drug development to execute fit-for-purpose comparative clinical trials.
Steven Suter, VMD, MS, PhD, DACVIM (Oncology)
Director of the Canine Bone Marrow Transplant Unit and Director of the Canine/Feline Oncology Diagnostic Laboratory, North Carolina State University
Dr. Steven Suter earned his VMD and PhD at the University of Pennsylvania and completed a medical oncology residency at UC Davis. Dr. Suter then joined the faculty at North Carolina State University in 2005 and is currently the Medical Director of the Canine Bone Marrow Transplant Unit and the Director of the Canine/Feline Oncology Diagnostic Laboratory. In addition, he helps run a very busy Medical Oncology service that diagnoses and treats companion animals with a wide variety of malignancies. His professional life is a marriage of both bench science and clinical practice, with many opportunities for overlap.
Douglas Thamm, VMD, DACVIM (Oncology)
Barbra Cox Anthony Professor and Director of Clinical Research, Colorado State University
Dr. Douglas Thamm received his VMD degree from the University of Pennsylvania. He completed an Oncology Residency at the University of Wisconsin, and was a researcher there for 5 additional years before joining the faculty at CSU in 2004. He has authored over 140 peer-reviewed publications and 20 book chapters in veterinary and basic cancer research, was Oncology Section Editor for the 2 most recent editions of Kirk’s Current Veterinary Therapy and is Co-Editor-In-Chief of the journal Veterinary and Comparative Oncology.
David Vail, DVM, MS, DACVIM (Oncology)
Professor and Barbara A. Suran Chair in Comparative Oncology, University of Wisconsin
Dr. David Vail received his DVM from the University of Saskatchewan in 1984 and completed an internship in small animal medicine and surgery at Colorado State University prior to practicing in his native western Canada for two years. He completed a residency in Medical Oncology at the Animal Cancer Center at Colorado State University in 1990. Dr. Vail has served as President of the Veterinary Cancer Society, Chairman of the Scientific Advisory Boards for the Morris Animal Foundation and the ACVIM Foundation, President of the Canine Comparative Oncology and Genomics Consortium (CCOGC), and past North American journal editor for Veterinary and Comparative Oncology. He is a founding member of the Comparative Oncology Trials consortium.